Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients

2026년 7월 1일 23:13 KST · 발표

기사 요약

Can-Fite's Phase 2a Namodenoson study met its safety endpoint and showed durable survival, supporting a Phase 2b chemotherapy trial.

기사 원문에서 발췌했어요.

댓글을 불러오고 있어요…